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Table S2: Mortality by HIV status and potential explanatory factors. 
HIV negative HIV positive 
Factor Level n Deaths Mortality rate per 
100 pyo (95% CI) 
n Deaths Mortality rate per 
100 pyo (95% CI) 
Overall 148 16 5.9 (3.6  ; 9.6) 140 51 21.4 (16.2  ; 28.1) 









5.6 (2.9  ; 10.7) 
4.4 (1.4  ; 13.6) 







19.7 (11.6 ; 33.2) 
17.1 (11.2 ; 26.3) 







10.9 (4.5  ; 26.1) 





22.1 (14.8 ; 33.0) 












10.3 (3.9  ; 27.5) 
3.0 (1.1  ; 8.1) 







26.3 (10.9 ; 63.2) 
24.2 (17.1 ; 34.2) 
15.0 (8.7  ; 25.9) 











6.0  (2.8  ; 12.5) 
40.4 (13.0 ; 125.2) 







23.6 (16.8 ; 33.2) 
186 (60 ; 576) 
15.4 (9.3 ; 25.6) 
Duration of TB 
symptoms 
(months) 









2.8 (1.2 ; 6.8) 
10.7 (5.1 ; 22.5) 







19.8 (14.3 ; 27.5) 
22.2 (11.9 ; 41.2) 













4.2 (2.3  ; 7.8) 
14.6 (5.5 ; 38.8) 







23.4 (17.4 ; 31.3) 
14.7 (6.1 ; 35.2) 





< 9  
9 – 15  










5.6 (1.8 ; 17.3) 
6.9 (3.1 ; 15.4) 
3.2 (0.8 ; 12.6) 









19.3 (10.0 ; 37.0) 
19.3 (11.0 ; 34.1) 
23.4 (13.6 ; 40.3) 
22.8 (14.2 ; 36.7) 
Resistance 
status 
Sensitive H and R 








3.5 (1.7 ; 7.0) 
6.4 (1.6 ; 25.7) 







17.9 (13.0 ; 24.6) 
32.4 (15.4 ; 68.0) 













10.7 (1.5 ; 76.0) 
3.9 (1.0 ; 15.5) 







23.0 (12.0 ; 44.3) 
20.8 (12.9 ; 33.5) 
19.4 (12.8 ; 29.5) 






5.5 (1.4 ; 21.8) 





25.5 (17.5 ; 37.2) 
16.4 (10.7 ; 25.1) 
Sputum AFB 
smear grade 









38.9 (14.6 ; 103.6) 
0 







26.1 (13.0 ; 52.2) 
14.9 (6.7 ; 33.1) 
22.1 (16.0 ; 30.4) 
DTP ≥ 7 days 





6.0 (2.3 ; 16.0) 





18.3 (10.6 ; 31.5) 












3.2  (1.5 ; 6.7) 
11.4 (5.1 ; 25.3) 







16.8 (11.9 ; 23.8) 
23.3 (12.9 ; 42.1) 
605 (303 ; 1210) 
CD42 (cells/ 
microL) and  
ART group3 
CD4 ≥ 200 
CD4 50-199, no ART 
CD4 50-199, ART 
CD4< 50, no ART 




















11.8 (6.7 ; 20.9) 
20.9 (10.9 ; 40.2) 
7.3 (2.3 ; 22.5) 
84.3 (55.0 ; 129.3) 
17.8 (7.4 ; 42.8)  
 
BMI=Body mass index H=Isoniazid R=Rifampicin MDR= Multi-drug resistant 
AFB=Acid fast bacilli DTP=Days to positive culture (BACTEC) ART=Antiretroviral therapy 
1 Category includes subjects that were fully adherent with treatment and those that missed a few 
doses. 
2 One HIV-infected subject did not have CD4 result. 
3 This is a time varying covariate; numbers are those for whom the category was their final 
category. 
 
 
 
